OBJECTIVE:To promote the application of single-disease entity quality control in children with community acquired pneumonia.METHODS:According to the requirements of "Single-disease Entity Quality Control Index" issued by Ministry of Public Health,280 children with community acquired pneumonia in our hospital were analyzed retrospectively in respect of admission standard,pathogen inspection,selection of antibiotics,medication time,treatment course,health education,clinical efficacy and cost of hospitalization.RESULTS & CONCLUSION:The diagnosis and treatment of children community acquired pneumonia in our hospital are in line with "Single-disease Entity of Pneumonia Quality Control Index" while detection rate of bacterial cultivation and the level of sensitivity test should be improved.

OBJECTIVETo learn the epidemiologic characteristics of rotavirus diarrhea in three hospitals under sentinel surveillance from August 2001 to July 2004 and to provide background information for developing and implementing rotavirus vaccine.

METHODSData from hospital-based rotavirus surveillance among children < 5 years old hospitalized with acute diarrhea was used. Patients' clinic information and feces specimens were collected. Specimens were tested and typed for rotavirus.

RESULTSTotally, 3121 specimens were tested and the detection rate of rotavirus was 51%. Among all the children with rotavirus diarrhea, 94% were < 2 years old. G3 (69.9%) was the most prevalent serotype followed by G1 (6.6%) and G2 (2.9%). P[8] was the most common genotype of rotavirus. The most common G-P combination identified in this study was P[8] G3 (64.0%). Seveal other combinations of minor frequency were also identified.

CONCLUSIONRotavirus infection was most commonly seen among children < 5 years old hospitalized with acute diarrhea in the three hospitals. It is important to develop and implement rotavirus vaccine to prevent and control severe rotavirus infection. Because of the diversity of rotavirus strains, it is necessary to perform rotavirus strain surveillance to understand the dynamic nature of viral transmission.

Child, Preschool ; China ; epidemiology ; Diarrhea ; epidemiology ; virology ; Feces ; virology ; Female ; Hospitals ; statistics & numerical data ; Humans ; Infant ; Infant, Newborn ; Male ; Rotavirus Infections ; epidemiology ; virology ; Sentinel Surveillance

Objective: To study the effect of oral metformin on the prognosis of patients with gastric cancer. Methods: The clinical data of 364 patients with gastric cancer admitted to the First Affiliated Hospital of Medical College of Shantou University from January 2013 to December 2017 were collected.The patients were divided into metformin group (31 cases), non-metformin group (35 cases) and non-diabetic group (298 cases) according to whether they were diabetes or treated with metformin.The mortality and survival of the three groups were compared. Results: The mortality rate was 12.9%(4/31) in the metformin group, 74.3%(26/35) in the non-metformin group, 52.0%(155/298) in the non-diabetic group, and the mortality rate in the metformin group was lower than that in the other two groups, the differences were statistically significant(χ²=10.081, P=0.001; χ²=7.681, P=0.006), and the metformin group had the lowest mortality rate.There was no statistically significant difference between the non-metformin group and the non-diabetic group (χ²=1.665, P=0.197). The survival time of the metformin group, non-metformin group and non-diabetic group were (29.017±16.254) months, (9.692±10.355) months and (16.748±8.526)months, respectively.The survival time of the metformin group was longer than that of the non-metformin group (t=5.827, P=0.000) and the non-diabetic group (t=6.843, P=0.000), and the survival time of the non-diabetic group was longer than that of the non-metformin group (t=4.523, P=0.000), and the overall survival of patients in the metformin group was prolonged.Clinical staging, treatment of gastric cancer, alcohol consumption and oral metformin treatment were independent factors influencing the prognosis of patients with gastric cancer. Conclusion Oral metformin can improve the prognosis of patients with gastric cancer and prolong the life of patients.